Clinical guide to managing chronic hypertension: Evidence-based assessment and long-term care

This clinical guide to managing chronic hypertension presents an evidence-based framework for diagnosis, risk assessment, treatment, and long-term follow-up. The 2025 American Heart Association and American College of Cardiology guideline replaced the 2017 adult hypertension guideline and was developed as a continuing reference for clinicians managing high blood pressure. 1

How hypertension is classified and confirmed

Adult blood pressure categories are based on systolic and diastolic measurements. Normal pressure is below 120/80 mm Hg, elevated pressure is 120 to 129 systolic with diastolic pressure below 80, stage 1 hypertension is 130 to 139 systolic or 80 to 89 diastolic, and stage 2 hypertension is at least 140 systolic or 90 diastolic. Either value can determine the higher category. 2

A diagnosis should not depend on one hurried office reading. Careful measurements are generally averaged across at least two readings on at least two occasions, with home or ambulatory monitoring used to identify white-coat hypertension or masked hypertension. Confirming elevated office readings outside the clinic is also recommended before treatment is initiated when clinically appropriate. 3

Initial clinical evaluation and risk assessment

Evaluation should establish the duration and pattern of high blood pressure, identify cardiovascular risk, and assess conditions that influence drug selection. Diabetes, cardiovascular disease, kidney disease, obesity, sleep-related breathing disorders, medication use, alcohol intake, tobacco exposure, and family history can materially affect the management plan. The 2025 guideline also emphasizes broader cardiovascular risk assessment and the use of the PREVENT risk calculator in place of the pooled cohort equations. 4

Persistent or unusually difficult-to-control hypertension requires attention to measurement accuracy, adherence, dosing, interacting medicines, and secondary causes. The 2025 guideline expands screening for primary aldosteronism to people with stage 2 or resistant hypertension. Other secondary causes may include renal artery disease, obstructive sleep apnea, or endocrine disorders, so the diagnostic approach should reflect the clinical pattern rather than rely on routine testing for every patient. 4

Lifestyle treatment as continuous care

Lifestyle treatment is a core component of chronic hypertension management, whether or not medication is prescribed. The principal measures include a DASH-style eating pattern, sodium reduction, regular aerobic and resistance activity, weight reduction when appropriate, moderation of alcohol, and adequate dietary potassium when clinically suitable. These interventions address several modifiable contributors to blood pressure and should be adapted to medical conditions, dietary needs, and social circumstances. 6

• A DASH-style dietary pattern emphasizes a structured approach to food quality and blood pressure control. 6
• Reduced sodium intake and regular physical activity are established components of nonpharmacological treatment. 6
• Potassium intake should be considered in the context of kidney function, medicines, and other clinical risks rather than increased automatically. 6

Medication selection and treatment targets

Common first-line medication classes include thiazide-type diuretics, calcium-channel blockers, and angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. ACE inhibitors and ARBs should not be combined. Medication selection depends on blood pressure level, kidney function, diabetes, cardiovascular disease, adverse-effect risk, pregnancy considerations, and patient preferences. 5

For many adults, the usual treatment goal is below 130/80 mm Hg, although the target must be individualized according to age, comorbidities, treatment tolerance, and clinician judgment. Stage 2 hypertension generally requires medication alongside lifestyle treatment, and two complementary first-line agents may be appropriate when pressure is substantially above the target. In diabetes, a goal below 130/80 mm Hg is commonly recommended when it can be achieved safely. 1

Monitoring, adherence, and resistant hypertension

Home blood pressure monitoring helps reveal day-to-day patterns and provides information between appointments. Long-term control depends on continued medication use, reliable measurement technique, follow-up, and adjustment when readings remain above goal or adverse effects develop. Treatment plans can fail because of missed doses, inadequate dosing, unaddressed lifestyle factors, comorbid conditions, social barriers, or inaccurate office measurements. 7

Resistant hypertension is generally defined as blood pressure above goal despite maximum or optimal doses of three medicines, including a diuretic. Before applying that label, clinicians should confirm adherence, rule out white-coat hypertension, review the regimen, and investigate secondary causes. A commonly recommended three-drug foundation includes a dihydropyridine calcium-channel blocker, an ACE inhibitor or ARB, and a thiazide diuretic. A mineralocorticoid receptor antagonist is the preferred fourth-line option in many patients. 5

Urgent situations and special populations

A reading above 180/120 mm Hg requires prompt reassessment. When it occurs with chest pain, shortness of breath, neurologic weakness, confusion, severe headache, or vision changes, emergency evaluation is warranted because these symptoms may indicate acute organ injury. A high reading without symptoms still requires timely clinical contact and repeat measurement rather than unsupervised medication changes. 8

Management becomes more individualized in pregnancy, chronic kidney disease, diabetes, older age, and established cardiovascular or neurologic disease. The 2025 guideline includes expanded recommendations for these populations, while NICE guidance separately identifies pregnancy-related hypertension as a distinct clinical area. Coordinated care may involve primary care, cardiology, nephrology, pharmacy, nursing, and other professionals when risk or treatment complexity is high. 1

Practical long-term management framework

A durable care plan links accurate diagnosis with risk-based treatment and repeated review. The sequence generally includes confirming blood pressure, assessing cardiovascular and kidney risk, identifying secondary causes when indicated, discussing lifestyle measures, selecting appropriate medication, checking response and tolerability, and revising the plan when control is inadequate. Shared decision-making is important because treatment intensity must balance expected benefit, adverse effects, functional status, and the burden of monitoring. 2

• Record home readings using a consistent technique and bring the results to clinical reviews. 3
• Do not stop prescribed antihypertensive medicine or combine ACE inhibitors with ARBs without clinical direction. 5
• Reassess persistent elevation for adherence, measurement error, secondary hypertension, and regimen quality. 5
• Treat emergency symptoms accompanying very high readings as urgent medical concerns. 8

Sources

1. 2025 AHA/ACC Adult High Blood Pressure Guideline, PubMed
2. NICE Guideline: Hypertension in Adults, NCBI Bookshelf
3. U.S. Preventive Services Task Force: Screening for Hypertension in Adults
4. Updates in the 2025 AHA/ACC Hypertension Guideline, Current Hypertension Reports
5. American Academy of Family Physicians: Resistant Hypertension in Adults
6. National Heart, Lung, and Blood Institute: High Blood Pressure
7. MedlinePlus: High Blood Pressure
8. American Heart Association: When High Blood Pressure Is an Emergency